Anderson CS; Huang Y; Lindley RI; Chen X; Arima H; Chen G; Li Q; Billot L; Delcourt C; Bath PM; Broderick JP; Demchuk AM; Donnan GA; Durham AC; Lavados PM; Lee TH; Levi C; Martins SO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Silva F; Song L; Thang NH; Wardlaw JM; Wang JG; Wang X; Woodward M; Chalmers J; Robinson TG; Martins SO; Kim JS; Stapf C; Simes RJ; Hankey GJ; Sandercock P; Bousser MG; Wong KSL; Scaria A; Hirakawa Y; Moullaali TJ; Carcel C; Gordon P; Fuentes-Patarroyo SX; Benito D; Chen R; Cao Y; Kunchok A; Winters S; Coutts S; Yoshimura S; You S; Yang J; Wu G; Zhang S; Manning L; Mistri A; Haunton V; Minhas J; Malavera A; Lim J; Liu L; Kumar NN; Tay N; Jenson K; Richtering S; Tucker S; Knight E; Ivanova E; Thembani E; Odgers E; Sanders E; Small S; Vaghasiya R; Armenis M; Donnelly P; Baig MA; Blacklock N; Naidu B; Monaghan H; Smith P; Glass P; Bai X; Li Q; Zhu P; Kong L; He R; Zhao H; Lv J; Jia H; Xi Z; Cong Y; Cui B, 2019, 'Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial',
The Lancet, vol. 393, pp. 877 - 888,
http://dx.doi.org/10.1016/S0140-6736(19)30038-8